


## **Declaration of Interests Register**

TA Committee C Publication Date: 30/09/2020

## **Topic: Naldemedine for treating opioid-induced constipation [ID1189]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments	
				Interest arose	Interest declared	Interest ceased		
Richard Nicholas	TAC Committee member	Indirect - financial	Richard Nicholas received a consultancy fee for taking part in an advisory board for a drug on Multiple Sclerosis from a comparator company, Novartis Pharmaceuticals.	Not specified	March 2020	Not specified	It was agreed that this declaration would not prevent Richard Nicholas from participating in this section of the meeting.	
Andrew Davies	TAC Clinical expert	Direct – financial	- Andrew Davies has participated in consultancy work for Kyowa Kirin on the drug, Naloxegol, which is a comparator drug to this appraisal. Lecturing in house and at satellite symposia. Research funding (investigator-initiated study)	2014	March 2020	Ongoing	It was agreed that the declarations would not prevent Andrew Davies from participating in this section of the meeting.	
			He participated in consultancy work for Sandoz which is a comparator company to this appraisal.	2019	March 2020	Ongoing		



	- He is the Chair of a guideline group for the management of constipation in patients with advanced cancer at the Multi-national Association of Supportive Care in Cancer.	2019	March 2020	2019	
	- Andrew Davies has received honoraria for participating in advisory boards from companies that market PAMORAs, such as AstraZeneca, Kyowa Kirin, Shionogi and Wyeth.	Not specified	March 2020	Not specified	